Results published in Journal of Vascular Surgery Cases, Innovations and Techniques (JVS-CIT) - - After up to 36 months of follow-up, patients demonstrated high limb salvage, low rates of infection, no ...
Developers of a cutting-edge lab-grown blood vessel designed to save life and limb in war zones and other emergency scenarios ...
DURHAM, N.C., March 25, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at ...
"We are pleased to enter into this facility with Avenue as it allows us to retire our existing indebtedness while providing the opportunity for additional non-dilutive financing in the future," said ...
Editor’s note: LimeLight is a new feature from WRAL TechWire offering another means of publishing noteworthy news. Be sure to check out more LimeLight worthy news at this link. DURHAM – Alpha ...
DURHAM – Humacyte, which officially merged with the special purpose acquisition company Alpha Healthcare Acquisition Corp. after shareholders of the SPAC voted to approve the move last week, is ...
DURHAM, N.C., May 13, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at ...
Humacyte Presents In Vivo Data on Biovascular Pancreas Transplantation for Type 1 Diabetes Treatment
Laboratory and preclinical models demonstrate biovascular pancreas platform technology may provide method to transplant islet cells that produce insulin in Type 1 diabetes patients Data presented at ...
The options for patients needing new blood vessels come with tradeoffs. Harvesting a vein requires a second surgery and additional recovery time. Synthetic implants can be readily pulled off the shelf ...
In mid-November, Benchmark analyst Bruce Jackson maintained a Buy rating on Humacyte, Inc. (NASDAQ:HUMA) stock and set a price target of $11. Humacyte, Inc. (NASDAQ:HUMA) engages in the development ...
Humacyte (HUMA) announced the publication of new, long-term data assessing the durability of Symvess in extremity arterial trauma patients in the Journal of Vascular Surgery Cases, Innovations and ...
DURHAM, N.C., March 25, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback